Donald W. DeGolyer is Director at Emergent BioSolutions Inc. (EBS). They have made 3 open-market trades across 1 company since 2024, most recently 2026-10-07.
CIK 0001583098
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EBS | 111,921 | $713K |
| ENDP | 6,547 | $2K |
| Total | $715K |
Shares reported on the most recent Form 4, priced at the 2026-10-07 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EBS | SELL · 10b5-1 | 2026-10-07 | 2026-10-07 | $7.09 | $126K | — | — | — |
| EBS | SELL · 10b5-1 | 2026-05-01 | 2026-05-04 | $8.40 | $130K | -7.8% | -10.8% | -16.7% |
| EBS | SELL | 2025-11-10 | 2025-11-12 | $10.54 | $375K | +2.1% | +7.7% | +4.2% |
| EBS | SELL | 2025-08-12 | 2025-08-13 | $8.65 | $136K | +6.7% | -5.6% | +26.2% |
| EBS | SELL | 2024-11-12 | 2024-11-14 | $10.91 | $273K | +11.3% | -1.6% | +5.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.